T 0034/10 (Extracellular domain influenza M2 membrane protein/VLAAMS) 12-02-2014

Reasons for the Decision

Admissibility of the appellant II's appeal

1. Appellant I argued that appellant II's statement of Grounds of Appeal does not fulfil the requirements of Article 12(2) RPBA (cf. point XIV supra).

2. The statement of Grounds of Appeal of appellant II is understood by the board as being based on a broad interpretation of claim 1 of the request upheld by the opposition division (i.e. Auxiliary Request 3 in the present appeal proceedings). It contains objections against the subject?matter of this claim which, in appellant II's view, allows two possible interpretations (cf. point XV supra). Appellant I's allegations that these arguments are incomplete and flawed do not prejudice the admissibility of the appeal itself. Equally the requirements of Article 12(2) RPBA are not contravened since the objections raised by appellant II are clear and comprehensible. Moreover, also the alleged presence of non?substantiated objections under Articles 54 and 56 EPC in appellant II's statement of Grounds of Appeal, does not per se render appellant II's appeal inadmissible, since there is no doubt that other, fully substantiated, objections have been provided with regard to Articles 84, 83 and 123(2),(3) EPC.

3. In consequence, the requirements of Article 12(2) RPBA are fulfilled and the appeal filed by appellant II is admissible.

Admissibility of the Main Request and of Auxiliary Requests 1 and 2

4. According to Article 12(4) RPBA, it is within the power of the board to hold inadmissible facts, evidence or requests which could have been presented in the first instance proceedings. Thus, for the board to reach a decision on the admissibility of the new claim requests, it is important to decide whether reasons have been given for their introduction at this stage of the proceedings and for not introducing them in opposition proceedings, whether their filing is a direct reply to the arguments of the opposition division raised in the decision under appeal or whether they address arguments or issues raised in earlier stages of the opposition proceedings (cf. "Case Law of the Boards of Appeal of the EPO", 7th edition 2013, IV.C.1.2.3, page 810).

5. Regarding appellant I's arguments on this issue (cf. point XIV supra), the board notes that:

Claim 1 of the Main Request contains features of claims 1 and 4 as granted (the presenting carrier is a (poly)peptide), of claim 16 as granted (for use in the preparation of a vaccine) and claim 19 as granted (wherein the antigen is in isolated form). However, claim 1 further requires the immunogenic extracellular part to be an immunoprotective fragment. As such, this feature was not present in claim 1 as granted (cf. point VIII supra). It is arguable whether it may be derivable from the use claims 16 and 27 and/or the product claim 17 as granted. Although in a different context, this feature was present in claim 1 of Auxiliary Request 1 before the opposition division which read: "1. An influenza antigen comprising a fusion product of (i) an immunoprotective extracellular part of an influenza M2 membrane protein ...".

Claim 1 of Auxiliary Request 1 reads as claim 1 of the Main Request but further contains the subject?matter of granted claim 13 (product?by?process feature).

Claim 1 of Auxiliary Request 2 reads as claim 1 of the Main Request but defines the immunogenic extracellular part as being the extracellular domain of the influenza M2 membrane protein. This definition was present in claim 1 of Auxiliary Request 2 before the opposition division which read: "1. An influenza antigen comprising a fusion product of (i) the extracellular part of an influenza M2 membrane protein ...".

6. Moreover, the amendments introduced into claim 1 of the Main Request and Auxiliary Requests 1 and 2 raise issues and objections that were not considered at first instance proceedings.

In particular, the feature "in isolated form" was not present in claim 1 of any of the claim requests filed during the first instance proceedings. Objections under Articles 123(2) and 84 EPC have been raised by appellant II against inter alia the introduction of this feature into claim 1 of the Main Request and of Auxiliary Requests 1 and 2. Without entering into the merit of these objections, the board notes that none of these objections could have been considered and examined at the proceedings before the opposition division. A similar situation arises for the introduction of the product?by?process feature into claim 1 of Auxiliary Request 1 which, since it was not present in claim 1 of any of the claim requests before the opposition division, also could not be considered and examined at the proceedings before the opposition division.

7. All three requests, the Main Request and Auxiliary Requests 1 and 2, were filed in appeal proceedings only and no reasons have been given either to explain their filing at this late stage, or why they could not have been filed earlier, i.e. at the first instance proceedings. The objections that these requests intend to overcome were present throughout the opposition proceedings. Thus, the patentee/appellant I could have addressed them during these proceedings.

8. Thus, in view of the above considerations, the board, exercising its discretion, does not admit the Main Request and Auxiliary Requests 1 and 2 into the appeal proceedings (Article 12(4) RPBA).

Admissibility of Auxiliary Requests 3 and 4

9. Auxiliary Request 3 is identical to the set of claims upheld by the opposition division, except for a correction in the dependency of claim 5 (there is also an uncorrected error in the dependency of claim 7). Claim 1 of Auxiliary Request 4 is a combination of claims 1 and 3 of Auxiliary Request 3.

10. None of these auxiliary requests raises issues or objections that were not considered by the opposition division during the opposition proceedings. Thus, these auxiliary requests are admitted into the appeal proceedings.

Auxiliary Request 3

Article 84 EPC

11. Appellant II raised a clarity objection against the feature of claim 1(i) of Auxiliary Request 3. In particular, with regard to the feature defining the extracellular part in claim 1 as being "... the 23 extracellular part of an influenza M2 membrane protein of influenza A virus ..." (cf. point XII supra), it was considered not to be clear whether this embraces only naturally occurring sequences of 23 amino acids or also artificially mutated or engineered sequences (cf. point XV supra).

12. A similar clarity objection was raised in opposition proceedings against the subject?matter of claim 1 of Auxiliary Request 2 then on file, which read as follows: "1. An influenza antigen comprising a fusion product of (i) the extracellular part of an influenza M2 membrane protein ..." (cf. point 5 supra). The opposition division considered this objection to be relevant since, in its view, "... the term "extracellular part" encompasses more embodiments than the sequence of aminoacids 1?23 of M2 ... (t)he claim encompasses sequences which may be shorter or longer than the 23 residues identified in the description, or include inserted aminoacids ...". The opposition division considered that "... (i)t is not clear what qualifies a sequence to fall under the definition of "extracellular part"..." (cf. page 8, point 5 of the decision under appeal).

13. The analysis of the opposition division in respect of this subject?matter is also relevant for the subject?matter of claim 1 of present Auxiliary Request 3 in which the length of this extracellular part has been limited to 23 amino acid residues (cf. point XII supra).

13.1 Although the extracellular domain of the influenza M2 membrane protein is highly conserved, a certain degree of variability cannot be excluded, as shown by the sequences disclosed in the patent itself (cf. Table 1 of the patent). Thus, the naturally occurring sequence of "the 23 amino acid sequence of the extracellular domain of the M2 membrane protein of influenza A virus" is not a single, unique, defined amino acid sequence but, in view of Table 1 of the patent, comprises several - at least three - different amino acid sequences. For this reason alone, there is already a certain degree of ambiguity in the subject-matter of claim 1 of Auxiliary Request 3.

13.2 Moreover, there is no limitation in part (i) of claim 1 of Auxiliary Request 3 to naturally occurring sequences of the influenza M2 membrane protein of influenza A virus. The wording of claim 1(i) does not clearly and unambiguously exclude other artificially mutated or engineered sequences derived from any of the possible naturally occurring sequences of "the 23 amino acid extracellular part of an influenza M2 membrane protein of influenza A virus". Therefore part (i) of claim 1 includes non?naturally occurring amino acid sequences. This interpretation is in line with the interpretation of the opposition division, which considered the term "the extracellular part" to encompass minor changes, in particular the substitution of amino acid residues.

13.3 Thus, it is not clear what qualifies a sequence to fall within the definition of "the 23 amino acid extracellular part of an influenza M2 membrane protein". It is questionable whether sequences of 23 amino acids comprising three, two or only one of the epitopes present in (known) naturally occurring sequences of an extracellular domain of the M2 membrane protein of influenza A virus fall within the wording of claim 1(i). In addition, it is unclear which degree of structural homology/identity and of functional similarity/identity is required for a sequence of 23 amino acids to be covered by the the wording of the claim.

13.4 This is all the more important since the preamble of claim 1 generally requires the claimed vaccine to comprise an "influenza antigen" without indicating any limitation to a particular type of influenza antigen and/or influenza virus type, not even to the influenza A virus (cf. page 2, paragraph [0002] of the patent).

14. In view of the above considerations, the board decides that the claims of Auxiliary Request 3 do not fulfil the requirements of Article 84 EPC.

Auxiliary Request 4

15. The objection under Article 84 EPC against Auxiliary Request 3 raised above, is overcome by the introduction into claim 1 of the three specific 23 amino acid sequences of the extracellular domain of the influenza M2 membrane proteins of influenza A virus, i.e. SEQ ID NO 1, 2 or 3 (cf. point XIII supra). This was also acknowledged by appellant II in its letter of 10 August 2010 (cf. point XV supra), in which no explicit objection was raised against the subject?matter of Auxiliary Request 4. Moreover, appellant II in its Grounds of Appeal did not raise any objection under Articles 123(2),(3), 54 and 56 EPC with regard to the claim request upheld by the opposition division (Auxiliary Request 3 in appeal proceedings), when claim 1 of this request was interpreted as being limited to the naturally occurring sequences of 23 amino acids of the extracellular domain of the influenza M2 membrane protein of influenza A virus (cf. page 4, paragraph (a) of appellant II's statement of Grounds of Appeal). Thus, as regards this embodiment, the decision of the opposition division was not contested by appellant II. By introducing the three specific SEQ ID NO's disclosed in the patent?in?suit into claim 1 of Auxiliary Request 4, there is no doubt that the claim is limited, only and exclusively, to naturally occurring sequences. The board sees no reason to differ from the findings of the opposition division as regards Articles 123(2),(3), 54 and 56 EPC.

16. In its Grounds of Appeal, appellant II raised an objection under Article 83 EPC against claim 1 of the claim request upheld by the opposition division (Auxiliary Request 3 in appeal proceedings), when the claim is interpreted as being limited to the naturally occurring sequences of 23 amino acids of the extracellular domain of the influenza M2 membrane protein of influenza A virus (cf. page 4, paragraph (a) of appellant II's statement of Grounds of Appeal). The fact that an immunoprotective response was demonstrated in the patent with a specific polypeptide presenting carrier (hepatitis B core protein) was not considered to render it credible that a similar response could be obtained with all possible polypeptide presenting carriers (cf. point XV supra). The same objection was raised in opposition proceedings against Auxiliary Request 3 then on file, but was considered not to be relevant by the opposition division (cf. page 10, last paragraph of the decision under appeal).

17. According to the established case law, a patent may only be objected to for lack of sufficient disclosure if there are serious doubts, substantiated by verifiable facts (cf. "Case Law", supra, II.C.6.1.4, page 318 and T 19/90, OJ EPO 1990, page 476). The board shares the view of the opposition division that the allegations put forward by appellant II do not suffice to raise serious doubts on the possibility of using polypeptide presenting carriers in general as defined in claim 1. In any case, the board fails to see any convincing verifiable fact on file to support the allegations of appellant II. Thus, the board sees no reason to differ from the findings of the opposition division as regards Article 83 EPC.

18. It follows from the above, that Auxiliary Request 4 fulfils all the requirements of the EPC.